GLSHQ (Gelesis Holdings) Common Stock: $0.01 Mil (As of Jun. 2023)


What is Gelesis Holdings Common Stock?

Gelesis Holdings GLSHQ -99.00% Common Stock is $0.01 Mil as of Jun. 2023.

Gelesis Holdings's quarterly common stock stayed the same from Dec. 2022 ($0.01 Mil) to Mar. 2023 ($0.01 Mil) and stayed the same from Mar. 2023 ($0.01 Mil) to Jun. 2023 ($0.01 Mil).

Gelesis Holdings's annual common stock increased from . 20 ($0.00 Mil) to Dec. 2021 ($0.00 Mil) and increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.01 Mil).

Gelesis Holdings Common Stock Historical Data

* Premium members only.

The historical data trend for Gelesis Holdings's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gelesis Holdings Common Stock Chart

Gelesis Holdings Annual Data
Trend Dec21 Dec22
Common Stock
0.00 0.01

Gelesis Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Gelesis Holdings Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.01 Mil mean?
Gelesis Holdings (GLSHQ) has a Common Stock of $0.01 Mil as of Jun. 2023. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Gelesis Holdings and its competitors.
Is Gelesis Holdings' Common Stock too high?
Gelesis Holdings' current Common Stock is $0.01 Mil.
How does Gelesis Holdings' Common Stock compare to RBSH and PPCB?
Gelesis Holdings' Common Stock of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Gelesis Holdings and its competitors. Gelesis Holdings's current Common Stock is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gelesis Holdings stock overvalued right now?
Gelesis Holdings (GLSHQ) has a current Common Stock of $0.01 Mil. The current Common Stock is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Gelesis Holdings (GLSHQ), the current Common Stock is $0.01 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gelesis Holdings Business Description

Address 501 Boylston Street, Suite 6102, Boston, MA, USA, 02116
Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.